Trakya Üniversiteler Birliği IV. Uluslararası Sağlık Bilimleri Kongresi (UTUC 2021), Online, Turkey, 11 November 2021
Aim: This study was conducted to investigate which anticoagulants and at what rates were used
to prevent hypercoagulopathy in this pandemic.
Methods: Necessary permissions were obtained from the non-interventional ethics committee
of the local university, the Ministry of Health and the local provincial health directorate. Until
July/2021, approximately 64 thousand PCR positive Covid-19 patients were diagnosed in our
province. Among these patients, with the Epi Info Stat Calc program, the expected prevalence
was 50%, the margin of error was 5%, and the pattern effect was 1, and the smallest sample
size was calculated as 659 at a 99% confidence level. A questionnaire was applied to them. 635
people completed the questionnaire.
Results: It was observed that the patients composed in our study were equally female (50.10%)
and male (49.90%). The mean age was 44.26 (SD±15.69) years (min:18, Max:88). Most of
them were university graduates (43.50%). Anticoagulants ((low molecular weight heparin
(LMWH) (n:225; 35.4%)) or acetylsalicylic acid (ASA) (n:89; 14.0%) were used in 49.40%
(n:314) of the patients. 73.57% (n:231) of the anticoagulant used was recommended by a doctor;
21.02% (n:66) of the people in their close circle (especially ASA) suggested; and 5.41% (n:17)
reported long-term use.
Conclusion: Cytokine storm and coagulation tendency are important complications that can
develop in Covid-19 infection. The use of anticoagulants is important to prevent this
complication. In our study, it was seen that 21.02% of the patients applied this treatment to
themselves without the recommendation of a doctor. Most of the anticoagulants used with
recommendation are ASA. Such anticoagulant treatments should be recommended by a
physician who is aware of the complications that may occur.
Keywords: Covid-19, pandemi, anticoagulant.